ES2491565T3 - Agente de transfección - Google Patents

Agente de transfección Download PDF

Info

Publication number
ES2491565T3
ES2491565T3 ES09809913.8T ES09809913T ES2491565T3 ES 2491565 T3 ES2491565 T3 ES 2491565T3 ES 09809913 T ES09809913 T ES 09809913T ES 2491565 T3 ES2491565 T3 ES 2491565T3
Authority
ES
Spain
Prior art keywords
transfection agent
aaaaaak
sirna
surgery
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09809913.8T
Other languages
English (en)
Inventor
Daizo Yoshida
Jiro Takei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Medical School Foundation
3D Matrix Ltd
Original Assignee
Nippon Medical School Foundation
3D Matrix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Medical School Foundation, 3D Matrix Ltd filed Critical Nippon Medical School Foundation
Application granted granted Critical
Publication of ES2491565T3 publication Critical patent/ES2491565T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de un tensioactivo peptídico que consiste en la secuencia de aminoácidos de AAAAAAK para la introducción de ARNip en células, en el que dicho uso no es un procedimiento para el tratamiento del cuerpo humano o animal por cirugía o terapia

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES09809913.8T 2008-08-27 2009-08-26 Agente de transfección Active ES2491565T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008217958 2008-08-27
JP2008217958 2008-08-27
PCT/JP2009/064814 WO2010024262A1 (ja) 2008-08-27 2009-08-26 トランスフェクション剤

Publications (1)

Publication Number Publication Date
ES2491565T3 true ES2491565T3 (es) 2014-09-08

Family

ID=41721429

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09809913.8T Active ES2491565T3 (es) 2008-08-27 2009-08-26 Agente de transfección

Country Status (8)

Country Link
US (1) US9133484B2 (es)
EP (1) EP2322608B1 (es)
JP (1) JP5606318B2 (es)
KR (1) KR101647521B1 (es)
CN (1) CN102131926A (es)
ES (1) ES2491565T3 (es)
SG (1) SG193822A1 (es)
WO (1) WO2010024262A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130236891A1 (en) * 2010-08-20 2013-09-12 3-D Matrix, Ltd. Method and composition for the treatment, prevention, and diagnosis of cancer containing or derived from cancer stem cells
CA2874003A1 (en) * 2012-05-31 2013-12-05 Sotirios KOUTSOPOULOS Sustained delivery of molecules using peptide surfactants and uses thereof
WO2018097335A1 (ja) * 2016-11-25 2018-05-31 国立大学法人 岡山大学 ホウ素中性子捕捉療法のための新規ｂｓｈ複合体
ES2956776T3 (es) 2017-11-09 2023-12-27 Purmx Therapeutics Inc Composición farmacéutica que comprende miARN-3140 para su uso en el tratamiento del cáncer
US11324703B2 (en) 2017-12-15 2022-05-10 3-D Matrix, Ltd. Surfactant peptide nanostructures and uses thereof in drug delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040961A1 (en) 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
WO2003006043A1 (en) * 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
WO2009018467A2 (en) * 2007-07-31 2009-02-05 Massachusetts Institute Of Technology Bio-sensing nanodevice

Also Published As

Publication number Publication date
EP2322608A4 (en) 2012-03-21
US9133484B2 (en) 2015-09-15
KR20110055693A (ko) 2011-05-25
JP5606318B2 (ja) 2014-10-15
US20110152203A1 (en) 2011-06-23
KR101647521B1 (ko) 2016-08-10
SG193822A1 (en) 2013-10-30
CN102131926A (zh) 2011-07-20
EP2322608B1 (en) 2014-05-21
JPWO2010024262A1 (ja) 2012-01-26
EP2322608A1 (en) 2011-05-18
WO2010024262A1 (ja) 2010-03-04

Similar Documents

Publication Publication Date Title
ES2512141T3 (es) Análogo peptídico de oxintomodulina
CL2020002026A1 (es) Inhibidor de fap.
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2491565T3 (es) Agente de transfección
ES2619322T3 (es) Agente inductor de inmunidad
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
ES2562651T3 (es) Lixisenatida para el uso en el tratamiento de la estenosis o/y la obstrucción del sistema de conductos pancreáticos
ES2494316T3 (es) Ingrediente activo novedoso en cicatrización y uso del mismo
BR112014013151A2 (pt) dispositivo de microagulhas incluindo um agente terapêutico peptídeo e um aminoácido, métodos para produzir e usar o dispositivo
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
UY30587A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasa s janus
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
BR112013002640A2 (pt) unidade de manipulação com sequência de implante forçada e mecanismo de acionamento independente
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
AR085951A1 (es) Dispositivo ortopedico expandible
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
ES2481641T3 (es) Uso de receptor inmunosupresor
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
CR9749A (es) Derivados de xantina como agonistas de hm74a selectivos
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.
AR063760A1 (es) Anticuerpos anti-factor d humanizados y usos de los mismos
AR083395A1 (es) Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico
BR112012033295A2 (pt) polipeptídeos curtos e contendo d-aminoácido para conjugados terapêuticos e seu uso
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.